Cord Blood News Volume 3.30 | Aug 4 2011

Successful Allogeneic Hematopoietic Stem Cell Transplantation for GATA2 Deficiency
Researchers performed nonmyeloablative hematopoietic stem cell transplantation in 6 patients with a newly described genetic immunodeficiency syndrome caused by mutations in GATA2. [Blood]

Ddx18 Is Essential for Cell-Cycle Progression in Zebrafish Hematopoietic Cells and Is Mutated in Human AML
The studies demonstrate the use of the zebrafish as a robust in vivo system for assessing the function of genes mutated in acute myeloid leukemia (AML), which will become increasingly important as more sequence variants are identified by next-generation resequencing technologies. [Blood]

Endothelial Progenitor Cells-Dependent Angiogenesis Requires Localization of the Full-Length Form of uPAR in Caveolae
Here investigators studied the pro-angiogenic role of urokinase-type plasminogen activator receptor (uPAR) in endothelial colony-forming cells, a cell population identified in human umbilical blood, that embodies all of the properties of an endothelial progenitor cell matched with a high proliferative rate. [Blood]

RUNX1–ETO Deregulates the Proliferation and Growth Factor Responsiveness of Human Hematopoietic Progenitor Cells Downstream of the Myeloid Transcription Factor, MYCT1
To determine whether increased MYCT1 expression recapitulates the RUNX1–ETO phenotype, researchers performed retroviral transduction of MYCT1 as a single molecular abnormality into hematopoietic cell lines and normal human cord blood-derived CD34+ progenitor cells. [Leukemia]

Shear Stress Regulates Adhesion and Rolling of CD44+ Leukemic and Hematopoietic Progenitor Cells on Hyaluronan
Researchers investigated quantitatively the adhesion behavior of leukemic cell lines and hematopoietic progenitor cells on thin films of the polysaccharides hyaluronan and alginate in a microfluidic system. [Biophys J]

Outcomes of a 1-Day Nonmyeloablative Salvage Regimen for Patients with Primary Graft Failure After Allogeneic Hematopoietic Cell Transplantation
Here, researchers report the outcome of 11 patients with hematologic diseases (median age, 44; range, 25–67 years, seven males) who received a 1-day reduced-intensity preparative regimen given as a re-transplantation for primary graft failure. [Bone Marrow Transplant]

The Cord Blood Apgar: A Novel Scoring System to Optimize Selection of Banked Cord Blood Grafts for Transplantation
The Cord Blood Apgar is strongly predictive of engraftment after umbilical cord blood transplantation and shows promise for optimizing screening of cord blood unit donors for transplantation. [Transfusion]

High Cord Blood Levels of the Th2-Associated Chemokines CCL17 and CCL22 Precede Allergy Development During the First 6 Years of Life
The aim of this study was to determine if cord blood T-helper 1 (Th1)- and Th2-associated chemokine levels are associated with allergy development during the first 6 years of life, allowing assessment of respiratory allergic symptoms usually developing in this period. [Pediatr Res]

CD14−/CD34+ Is the Founding Population of Umbilical Cord Blood-Derived Endothelial Progenitor Cells and Angiogenin1 Is an Important Factor Promoting the Colony Formation
In this study, researchers explored the origin of umbilical cord blood-derived endothelial progenitor cells by culturing CD14+ or CD14− subpopulation separately and co-culturing these two subpopulations either with or without transwells. [Ann Hematol]

National Center for Regenerative Medicine, Cleveland Clinic and the Cleveland Cord Blood Center Collaborate with ImageIQ® to Improve Umbilical Cord Blood Stem Cell Characterization
ImageIQ Inc., announced that it will partner with the National Center for Regenerative Medicine at Case Western Reserve University, Cleveland Clinic and the Cleveland Cord Blood Center to develop customized image acquisition and analysis software as part of the three-year biomedical technology and innovation project through an Ohio Third Frontier Program grant. [Reuters]

Cord Blood America: Matt Schissler: Growing the Company
Cord Blood America founder and CEO Matthew Schissler launched his company in the midst of a heated debate over the morality of using stem cells to treat disease. [Cord Blood America Inc. Press Release]

Visit our events page to see a complete list of events in the cord blood community.

Scientist (iPSC) (STEMCELL Technologies)

Industrial Postdoctoral Research Fellow (Regenerative Medicine Cell Therapy) (Tissue Regeneration Therapeutics Inc.)

Cord Blood Procurement Specialist (Karmanos Cancer Institute)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.